sabamirza1d ago

OncoTherapy Science shares struggle amid clinical delays and prolonged investor confidence concerns recently.

#OncoTherapyScience #BiotechStocks #ClinicalTrials #StockMarket

https://meyka.com/blog/oncotherapy-science-stock-slumps-44-in-three-years-on-clinical-delays-2105/

OncoTherapy Science Stock Slumps 44% in Three Years on Clinical Delays | Meyka

4564.T stock trades at ¥20.0 with D+ rating. Biotech firm faces clinical trial headwinds and negative earnings outlook through 2026.

sabamirzaMay 15

IntegraGen SA stock plunges sharply as profitability concerns pressure struggling biotech company shares.

#IntegraGen #BiotechStocks #StockMarket #MarketNews

https://meyka.com/blog/integragen-sa-stock-tumbles-28-as-biotech-faces-profitability-headwinds-1505/

IntegraGen SA Stock Tumbles 28% as Biotech Faces Profitability Headwinds | Meyka

ALINT.PA stock crashes 28.3% on weak fundamentals. Genomics firm reports negative earnings, cash burn, and Meyka AI rates it a HOLD with C grade.

sabamirzaMay 15

OBSN.SW stock collapses dramatically as biotech clinical trial challenges pressure investor confidence severely.

#OBSNSW #BiotechStocks #ClinicalTrials #StockMarket

https://meyka.com/blog/obseva-sa-obsnsw-crashes-769-as-biotech-faces-clinical-trial-headwinds-1505/

ObsEva S.A. (OBSN.SW) Crashes 76.9% as Biotech Faces Clinical Trial Headwinds | Meyka

OBSN.SW stock plummets 76.9% to CHF 0.0012. ObsEva S.A. biotech faces clinical trial challenges in reproductive health pipeline.

sabamirzaMay 12

MBX Biosciences CMO expands holdings through significant stock options acquisition filed recently.

#MBXBiosciences #StockOptions #InsiderTrading #BiotechStocks

https://meyka.com/blog/mbx-biosciences-cmo-acquires-55k-stock-options-on-may-8-2026-1205/

MBX Biosciences CMO Acquires 55K Stock Options on May 8, 2026 | Meyka

MBX CMO Azoulay Salomon acquired 55,000 stock options valued at $575,300 on May 8, 2026, per SEC filing insider transaction disclosure.

Yonhap Infomax NewsJan 23
South Korea's KOSPI closed at a record high just below 5,000, while the KOSDAQ ended near 1,000, led by strong gains in biotech stocks and foreign institutional buying.
#YonhapInfomax #KOSPI #KOSDAQ #BiotechStocks #ForeignInvestors #RecordHighs #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=101767
[Market Close] KOSPI, KOSDAQ End Just Shy of 5,000 and 1,000 Mark

South Korea's KOSPI closed at a record high just below 5,000, while the KOSDAQ ended near 1,000, led by strong gains in biotech stocks and foreign institutional buying.

Yonhap Infomax
Yonhap Infomax NewsNov 28
South Korea’s KOSPI index fell 1.5% amid foreign selling and AI valuation concerns, while KOSDAQ surged 3.5% on policy hopes and biotech gains as US markets closed for Thanksgiving.
#YonhapInfomax #KOSPI #KOSDAQ #ForeignInvestors #EliLilly #BiotechStocks #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=93090
Sharp Divergence in South Korean Markets Amid US Holiday—KOSPI Plunges 1.5% While KOSDAQ Surges 3.5%

South Korea’s KOSPI index fell 1.5% amid foreign selling and AI valuation concerns, while KOSDAQ surged 3.5% on policy hopes and biotech gains as US markets closed for Thanksgiving.

Yonhap Infomax
Yonhap Infomax NewsNov 28
The KOSDAQ index surged nearly 3% on policy optimism and a biotech rally, outpacing the KOSPI, as investors anticipate government measures to boost the market.
#YonhapInfomax #KOSDAQ #PolicyMeasures #BiotechStocks #EliLilly #InvestorSentiment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=93033
Policy Optimism and Biotech Rally Drive KOSDAQ to 3% Surge

The KOSDAQ index surged nearly 3% on policy optimism and a biotech rally, outpacing the KOSPI, as investors anticipate government measures to boost the market.

Yonhap Infomax
Yonhap Infomax NewsAug 27, 2025
South Korea’s KOSPI closed up 0.25% as shipbuilding stocks surged on merger and export hopes, while KOSDAQ was flat with biotech gains offset by losses in robotics and batteries.
#YonhapInfomax #KOSPI #Shipbuilding #HDHyundai #KOSDAQ #BiotechStocks #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=78944
Yonhap Infomax NewsAug 5, 2025
Asian stock markets rallied as weaker US jobs data fueled expectations of a Federal Reserve rate cut, with major indices in Japan, China, Hong Kong, and Taiwan closing higher. Japanese government bond yields fell, the yuan strengthened, and biotech shares led gains in Hong Kong.
#YonhapInfomax #FederalReserve #Nikkei225 #USJobsData #YuanAppreciation #BiotechStocks #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=75675
[Asian Stock Markets Summary]Asian Markets Rally on Hopes of US Rate Cut

Asian stock markets rallied as weaker US jobs data fueled expectations of a Federal Reserve rate cut, with major indices in Japan, China, Hong Kong, and Taiwan closing higher. Japanese government bond yields fell, the yuan strengthened, and biotech shares led gains in Hong Kong.

Yonhap Infomax
News24mediaJul 21, 2025

🚨 Anthem Biosciences makes a stellar market debut!
📈 Listed at ₹723 — a 27% premium over the IPO price of ₹570.
💰 IPO subscribed 63.86 times!

With a 30% YoY revenue growth and global CRDMO dominance, is Anthem India’s next biotech star?
📊 FY25 Net Profit: ₹451 Cr | EBITDA Margin: 36.8%

🔗 Read the full analysis to know if you should invest.

#AnthemBiosciences #StockMarketIndia #IPOListing #BiotechStocks #CRDMO #PharmaInvesting #AnthemSharePrice https://news24media.org/anthem-biosciences-share-price/

📈 Anthem Biosciences share Price Surges 27% on Market Debut: Should You Invest? - News 24 Media

Anthem Biosciences share Price News Today (July 21, 2025): Anthem Biosciences made an impressive entry into the Indian stock market on Monday, debuting at ₹723 per share on the BSE — a solid 27% premium over its IPO issue price of ₹570.

News 24 Media